Literature DB >> 9610532

Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT).

S B King1, D O Williams, P Chougule, J L Klein, R Waksman, R Hilstead, J Macdonald, K Anderberg, I R Crocker.   

Abstract

BACKGROUND: In the porcine overstretch injury model of restenosis, endovascular beta-radiation reduces neointima formation. To determine whether this therapy could be applied to patients with coronary artery disease, a special device was developed to allow delivery of 12 encapsulated 90Sr/Y sources, measuring a total of 30 mm, to various sites within the coronary arterial tree. This study was designed to evaluate the feasibility of the delivery of 12, 14, or 16 Gy at 2 mm after balloon angioplasty of stenoses of native coronary vessels. METHODS AND
RESULTS: Delivery of beta-radiation was attempted in 23 patients after successful balloon angioplasty. Source delivery was successful in 21 of the 23 patients (91%). There was no in-hospital or 30-day morbidity or mortality. Follow-up quantitative coronary arteriography in 20 patients demonstrated a late loss of 0.05 mm, a late loss index of 4%, and a restenosis rate of 15%. The use of the beta-emitter 90Sr/Y significantly reduced treatment time and operator exposure compared with previous trials with the gamma-emitter 192Ir.
CONCLUSIONS: In this study, the administration of endovascular beta-radiation after angioplasty was safe and feasible and substantially altered the postangioplasty late lumen loss, resulting in a lower-than-expected rate of restenosis. On the basis of these encouraging results, a multicenter, randomized trial with operators and patients blinded to treatment assignment is planned.

Entities:  

Mesh:

Year:  1998        PMID: 9610532     DOI: 10.1161/01.cir.97.20.2025

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Early and late effects of radiation treatment for prevention of coronary restenosis: a critical appraisal.

Authors:  O F Bertrand; S Lehnert; R Mongrain; M G Bourassa
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

2.  Intravascular radiotherapy: restenosis and more?

Authors:  P Wexberg; M Gottsauner-Wolf
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

3.  Monte Carlo dose simulation for intracoronary radiation therapy with a rhenium 188 solution-filled balloon with contrast medium.

Authors:  Eun-Hee Kim; Dae Hyuk Moon; Seung-Jun Oh; Chang-Woon Choi; Sang-Moo Lim; Myeong-Ki Hong; Seong-Wook Park
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

4.  An organotypical in vitro model for vascular tissue remodelling and its application to study radiation effects.

Authors:  M Verbeke; H Thierens; Y Taeymans; L De Ridder
Journal:  Cytotechnology       Date:  2000-11       Impact factor: 2.058

5.  Intracoronary radiation using radioisotope solution-filled balloons.

Authors:  J Weinberger
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

Review 6.  Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations.

Authors:  R Waksman
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

7.  Intracoronary radiation with a 32P source wire.

Authors:  D P Lee; S Lo; K M Forster; D J Tate; A Raizner; S N Oesterle
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

8.  Intracoronary radiation therapy: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2001-12-01

9.  Catheter based intracoronary brachytherapy leads to increased platelet activation.

Authors:  M Jaster; V Fuster; P Rosenthal; M Pauschinger; Q-V Tran; D Janssen; W Hinkelbein; P Schwimmbeck; H-P Schultheiss; U Rauch
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

Review 10.  Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus.

Authors:  Ian J Sarembock
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.